Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2014

View Archived Issues

Researchers confirm ambidextrous chaperone activity of GroEL/ES

Alirocumab lowers the rate of major CV events in patients with hypercholesterolemia

4D pharma profiles pipeline progress

Jakavi launched in Japan

APD-811 granted FDA orphan drug status for pulmonary arterial hypertension

FDA grants fast track designation to motolimod for ovarian cancer

Xention and Servier begin first phase II study of XEN-D0103

Ozurdex approved in the E.U. for the treatment of diabetic macular edema

HanAll BioPharma discloses new AMPK activators

Zytiga launched in Japan for prostate cancer

FDA accepts NDA filing for eluxadoline, grants priority review

Novel NS5B inhibitors disclosed by Bristol-Myers Squibb

Amgen submits MAAs for talimogene laherparepvec and evolocumab in the E.U.

Merck & Co. synthesizes novel IRAK inhibitors

Reslizumab reduces asthma exacerbations in two pivotal phase III trials

Mitsubishi Tanabe Pharma and Daiichi Sankyo launch Canaglu in Japan

Draconis Pharma patents new EP4 receptor antagonists

Opdivo launched in Japan for unresectable melanoma

Nuplazid receives FDA breakthrough therapy designation for Parkinson's disease psychosis

Hua Medicine patents new mGlu5 receptor antagonists

Lundbeck launches Northera in U.S. for symptomatic neurogenic orthostatic hypotension

Final results of PARADIGM-HF and other studies presented for LCZ-696

Kaken launches Clenafin in Japan for tinea unguium

European orphan drug designations for CER-001 in apoA-I and ABCA1 deficiencies

Methotrexate receives FDA orphan drug status for myasthenia gravis

Phase II results for EPI-743 in Rett syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...